Legal & General Group Plc increase holdings in ImmuPharma PLC

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”) confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma’s total voting rights figure of 132,522,985 Ordinary Shares.

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: “We are delighted to be able to disclose Legal & General’s increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful GBP4.1 million fundraising demonstrating its continued support for ImmuPharma.”

Full disclosure of the TR1 is shown below:

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 
----------------------------------------------- 
 
 
 
 1. Identity of the issuer or                                         ImmuPharma Plc 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: 
------------------------------------------------------------  ----------------------------- 
 2. Reason for the notification (please tick the appropriate 
  box or boxes): 
------------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                                 Yes 
---------------------------------------------------------------  -------------------------- 
 
   An acquisition or disposal of qualifying financial 
   instruments which may result in the acquisition 
   of shares already issued to which voting rights 
   are attached. 
---------------------------------------------------------------  -------------------------- 
 
   An acquisition or disposal of instruments with 
   similar economic effect to qualifying financial 
   instruments 
---------------------------------------------------------------  -------------------------- 
 An event changing the breakdown of voting rights 
---------------------------------------------------------------  -------------------------- 
 
   Other (please 
   specify): 
--------------------------------------------------------  -----  -------------------------- 
 3. Full name of person(s)                                     Legal & General Group Plc 
  subject to the                                                          (L&G) 
  notification obligation: 
----------------------------------------------------------  ------------------------------- 
 4. Full name of shareholder(s)                                Legal & General Assurance 
  (if different from 3.):                                        Society Limited (LGAS) 
----------------------------------------------------------  ------------------------------- 
                                                                     16 March 2017 
   5. Date of the transaction 
   and date on 
   which the threshold is 
   crossed or 
   reached: 
----------------------------------------------------------  ------------------------------- 
 6. Date on which issuer                                             17 March 2017 
  notified: 
----------------------------------------------------------  ------------------------------- 
 7. Threshold(s) that is/are                                         L&G (Above 3%) 
  crossed or 
  reached: 
----------------------------------------------------------  ------------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares 
---------------------------------------------------------------------------------------------------------- 
 Class/type               Situation                            Resulting situation after the 
  of                       previous                                triggering transaction 
  shares               to the triggering 
                          transaction 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  -------------------------------  ---------------------------------------------------------- 
                    Number          Number                        Number of voting         % of voting 
                      of               of                              rights                 rights 
                    Shares           Voting 
                                     Rights 
-------------  ---------------  --------------  ------------  -----------------------  ------------------- 
                                                   Number        Direct     Indirect    Direct    Indirect 
                                                  of shares 
-------------    -------------   -------------  ------------  -----------  ----------  --------  --------- 
 ORD GBP 
  0.10                      Below 3%              4,446,545     4,446,545       -        3.35%       - 
-------------  -------------------------------  ------------  -----------  ----------  --------
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because